# Patient preferences and priorities for the design of an acute kidney injury prevention trial: Findings from a consensus workshop

#### **Supplemental Material**

Supplemental Table 1. Vignettes

Supplemental Table 2. Workshop topic guide

Supplemental Table 3. Post-workshop evaluation

Supplemental Figure 1. Summary of findings from post-workshop evaluation

Supplemental Table 4. Guidance for Reporting Involvement of Patients and Public (GRIPP2) short form

### Supplemental Table 1. Vignettes

#### Vignette A - Edgar N. (patient)

Edgar is a 74-year-old man with chronic kidney disease, high blood pressure, and diabetes. The medications he takes to treat these conditions include ramipril, metformin, and atorvastatin. He is a retired accountant and lives with his wife. He has two children and 6 grandchildren. He quit smoking about 10 years ago and drinks two glasses of wine per week.

Edgar is admitted to hospital with a heart attack, and his cardiologist tells him he needs to have a coronary angiogram to see if there are any blood vessel narrowings that could be treated with coronary stents or bypass surgery. His doctor tells him there is a chance his kidney function will get worse after the angiogram.

#### Definitions:

**Ramipril** – medication used to treat high blood pressure

**Metformin** – medication used to treat diabetes

Atorvastatin – medication used to treat high cholesterol

**Creatinine** – a blood test to measure kidney function

**eGFR** – a calculation based on creatinine that estimates how well the kidneys are filtering (i.e., what % they are working)

Angiogram – a test using contrast dye to determine if

Edgar's kidney function in hospital is similar to at home -

creatinine is 150 umol/L, which is equivalent to 42% kidney function (i.e., eGFR 42 ml/min).

Edgar's nurse mentions that he might be eligible for the PONTIAC trial.

#### Vignette B – Elena R. (patient)

Elena is a 32-year-old woman who was healthy and took no medications prior to her cervical cancer diagnosis 1 month ago. She has been in a relationship with her partner, Maria, for 6 years and has no children, although they have discussed plans for children in the future. She works as an elementary school teacher but has taken a leave of absence to focus on her health.

Together with her partner and cancer care team, Elena has decided on a treatment plan that includes radiation therapy and chemotherapy. She read on the internet that one of the chemotherapy medicines her care team plans on using, cisplatin, can cause kidney damage. She recalls her family doctor telling her that her kidneys were "normal" on recent bloodwork. Elena plans on asking her doctors about it when she comes into hospital for her cancer treatment next week.

Elena's oncologist suggests she consider enrolling in the PONTIAC trial.

#### Vignette C - Roberta D. (caregiver)

Roberta is a 45-year-old woman who is married and has two school-aged children. Her husband, Michael, was admitted to ICU this morning for sepsis due to a bacteria called Staphylococcus aureus that they believe was caused by a skin infection on his leg. Michael struggles with obesity, has diabetes and sleep apnea, and takes metformin and ramipril. His kidney function was previously normal (above 60%, or eGFR greater than 60 ml/min), although he has had high amounts of albumin protein in his urine due to the diabetes.

When he presented to hospital, Michael had signs of acute kidney injury – his creatinine was elevated at 180 umol/L from his previous result of 80 umol/L 2 months ago. Because Michael is so sick, he requires medications to raise his blood pressure and a ventilator to help him breathe. Michael is sedated and cannot speak for himself, so his ICU care team speaks with Roberta about the proposed treatment plan that includes an antibiotic called vancomycin. They explain that in some people, this antibiotic can lead to further kidney injury.

#### **Definitions:**

ICU – Intensive Care Unit

Sepsis – a severe blood infection

**Metformin** – medication used to treat diabetes

**Ramipril** – medication used to treat high blood pressure

**Creatinine** – a blood test to measure kidney function

eGFR – a calculation based on creatinine that estimates how well the kidneys are filtering (i.e., what % they are working)

Acute kidney injury – sudden damage to the kidneys so that they cannot filter properly; potential causes include severe illness, certain medications, inflammation, or blockage of urine

The care team asks Roberta how she would like to proceed and mentions enrolment in the PONTIAC trial.

# Supplemental Table 2. Workshop topic guide

	Breakout session #1 – T	Copic: Recruitment and	consent processes
--	-------------------------	------------------------	-------------------

Introduction	In this session, we will be talking about options for the recruitment and consent processes for the trial. We want to explore your opinions on the different ways we could design the recruitment and consent processes because it can be challenging to identify eligible patients for clinical trials like this one and we want recruitment to be as efficient as possible (identify as many eligible patients as quickly as possible). This is one of the largest barriers to successfully completing clinical trials, so we would like to consider innovative approaches as long as they are felt to acceptable to patients. Let's first spend a few minutes reviewing a vignette that we will use for this discussion.		
	<b>Vignette A – Edgar N. (patient)</b> Edgar is a 74-year-old man with chronic kidney disease, high blood pressure, and diabetes. The medications he takes to treat these conditions include ramipril, metformin, and atorvastatin. He is a retired accountant and lives with his wife. He has two children and 6 grandchildren. He quit smoking about 10 years ago and drinks two glasses of wine per week.		
	Edgar is admitted to hospital with a heart attack, and his cardiologist tells him he needs to have a coronary angiogram to see if there are any blood vessel narrowings that could be treated with coronary stents or bypass surgery. His doctor tells him there is a chance his kidney function will get worse after the angiogram.		
	Edgar's kidney function in hospital is similar to at home – creatinine is 150 umol/L, which is equivalent to 42% kidney function (i.e., eGFR 42 ml/min).		
	Edgar's nurse mentions that he might be eligible for the PONTIAC trial.		
Questions/Discussion		Notes:	
	Tell me more about how you feel about the acceptability of these approaches. (e.g.		

	D1 1 1 1	
	Balancing giving you the	
	greatest opportunity to	
	participate in the trial versus	
	protecting your health care	
	information and privacy)	
2.	How do you feel about a	
	waiver of consent to access	
	your health records to	
	determine if you are eligible	
	for the trial before you are	
	approached for informed	
	consent?	
	(e.g., using the information	
	already captured in the	
	hospital electronic medical	
	record)	
	TT 11 1 / 1	
3.	Tell me about how you or a	
	member of your family (if	
	you were too sick to make the	
	decision for yourself) would	
	want to be provided with	
	information about the study	
	as part of the informed	
	consent process (eg.	
	explanation from the study	
	coordinator in person, a video	
	explaining the study, via a	
	telephone call with study	
	coordinator, would you be	
	comfortable receiving the	
	information required to	
	decide on participation from	
	the doctor or nurse looking	
	after you in hospital).	

# Breakout session #2 – Topic: Intervention delivery

Introduction	In this group, we will be talking about the way the medical	
	intervention, consisting of the drug cilastatin or placebo, would be	
	delivered. We want to understand what you feel are acceptable ways	
	to receive the medication so you would be willing to participate in the	
	trial, recognizing that it must be delivered via an intravenous route	
	(i.e. a needle into a blood vessel) and the time you are at risk of	

	<ul> <li>kidney damage from a drug could vary, and even extend beyond the time you are in hospital. Let's spend a few minutes reviewing the vignette we will be using for this discussion.</li> <li>Vignette B – Elena R. (patient)</li> <li>Elena is a 32-year-old woman who was healthy and took no medications prior to her cervical cancer diagnosis 1 month ago. She has been in a relationship with her partner, Maria, for 6 years and has no children, although they have discussed plans for children in the future. She works as an elementary school teacher but has taken a leave of absence to focus on her health.</li> <li>Together with her partner and cancer care team, Elena has decided on a treatment plan that includes radiation therapy and chemotherapy. She read on the internet that one of the chemotherapy medicines her care team plans on using, <i>cisplatin</i>, can cause kidney damage. She recalls her family doctor telling her that her kidneys were "normal" on recent bloodwork. Elena plans on asking her doctors about it when she comes into hospital for her first cancer treatment next week.</li> </ul>	
	Elena's oncologist suggests she consider enrolling in the PONTIAC trial.	
Questions/Discussion	1. How would you feel about participating in the trial with the intervention requiring a placement of an intravenous (IV) needle? (if I already had an IV in place, if I didn't already have an IV and had to have one placed)       Notes:         Do you think this would influence your participation in the trial?       Notes:	
	2. How would you feel about receiving the cilastatin or placebo at multiple times in hospital or clinic visits when you are being exposed to nephrotoxic medication and would this affect your participation in the trial?	

3.	Would knowing you would	
	have to return to a clinic or	
	receive intravenous	
	medication after you are	
	discharged home influence	
	your willingness to participate	
	in the trial?	

# Breakout session #3 – Topic: Patient-prioritized outcomes

Introduction	In this group, we will be talking a	bout the selection of outcomes	
	that will be measured to determine how effective the medication is. We want to identify the outcomes that are most important for		
	•	ify a primary outcome, which will	
	study to be confident in the result	s. Other outcomes can also	
	measured and should be pre-specified before the study starts, though the additional costs and complexity of measuring them are important considerations.		
	Vignette C – Roberta D. (caregi	ver)	
	Roberta is a 45-year-old woman v	who is married and has two school-	
	aged children. Her husband, Mich morning for sepsis due to a bacter		
	that they believe was caused by a	skin infection on his leg. Michael	
	struggles with obesity, has diabetes and sleep apnea, and takes metformin and ramipril. His kidney function was previously normal		
	(above 60%, or eGFR greater than 60 ml/min), although he has had		
	high amounts of albumin protein	in his urine due to the diabetes.	
	When he presented to hospital, M		
	result of 80 umol/L 2 months ago.	ed at 180 umol/L from his previous Because Michael is so sick, he	
	requires medications to raise his blood pressure and a ventilator to		
	help him breathe. Michael is sedated and cannot speak for himself,		
	so his ICU care team speaks with Roberta about the proposed treatment plan that includes an antibiotic called vancomycin. They		
	explain that in some people, this antibiotic can lead to further		
	kidney injury.		
	The care team asks Roberta how she would like to proceed and		
	mentions enrolment in the PONTIAC trial.		
Questions/Discussion	1. Review the list and description of the different	Notes:	


	categories of clinical outcomes (these include surrogate and patient- important clinical outcomes, patient-reported health status measures, and measures of experience)? Which of these are important outcomes to you?	
2.	Which outcomes do you feel are most important to you?	
3.	Which type of patient reported health status measure would you want to know whether the intervention could improve?	

# Supplemental Table 3. Post-workshop evaluation

	Strongly disagree				Strongly
		2	3	4	agree 5
1. The goal of the workshop was described clearly.					
2. The program was well paced within the allotted time.					
3. The facilitators were good communicators.					
4. The material was presented in an organized manner.					
5. The vignettes aided the topic discussion.					
6. The facilitators were knowledgeable about the topic.					
7. My opinions were captured in the summaries provided by the facilitators back to the large group and in the voting options listed at the end of the workshop.					
8. I feel the final voting results reflect the opinions and discussions of patients who participated in the workshop.					
9. Given the objectives, this workshop was:	🗅 Too sh	ort	Right leng	gth 🗅	Too long
10. Please rate the following:	Excellent	Very good	Good	Fair	Poor
a. Workshop reading material					
b. Workshop organization					
c. Instructions					
What did you most appreciate/enjoy/think was bes Do you have any suggestions for improvement?	st about th	e worksho	op?		

### Supplemental Figure 1. Summary of findings from post-workshop evaluation

Twelve of the thirteen participants completed the evaluation. The following graph illustrates participant responses to the evaluation questions:



All participants agreed that the goal of the workshop was clearly described. Nine participants either strongly or somewhat agreed that the vignettes aided the discussion around the three topic areas. Most participants reported that the final voting results accurately reflected the discussion and their opinions (11/12), while 7/12 participants felt that their opinions were captured in summaries presented by the facilitators during the large group sessions.

**Supplemental Table 4.** Guidance for Reporting Involvement of Patients and Public (GRIPP2) short form

Se	ction and Topic	Item	<b>Reported on page No</b>
1.	Aim	Report the aim of PPI in the study	5
2.	Methods	Provide a clear description of the	5-9
		methods used for PPI in the study	
3.	Study results	Outcomes-Report the results of PPI in the	9-13
		study, including both positive and	
		negative outcomes	
4.	Discussion and	Outcomes-Comment on the extent to	13-17
	conclusions	which PPIs influenced the study overall.	
		Describe positive and negative effects	
5.	Reflections/critical	Comment critically on the study,	8-9, 16-17
	perspective	reflecting on the things that went well	
		and those that did not, so others can learn	
		from this experience	

Abbreviations: PPI, patient and public involvement